Real World Study of Lapatinib Among Metastatic Breast Cancer Patients

Lapatinib Resistance in Patients With Breast Cancer

NCT00898573 ·Status: WITHDRAWN

Safety and Efficacy of Lapatinib Plus Trastuzumab or Lapatinib Plus Capecitabine in Metastatic Breast Cancer

NCT01985893 ·Status: WITHDRAWN ·Phase: PHASE2

A Prospective, Multicenter, Observational Cohort Study to Evaluate the Efficacy and Safety of a Novel Anti-tumor Drug As a Radiosensitizer in Patients with Advanced Breast Cancer Brain Metastasis.

NCT06839547 ·Status: NOT_YET_RECRUITING

Lapatinib in Treating Patients With Advanced or Metastatic Breast Cancer That Overexpresses HER2

NCT00544804 ·Status: COMPLETED ·Phase: PHASE1

A Trial Comparing S1 Generic With Capecitabine in Metastatic Breast Cancer (MBC)

NCT01655992 ·Status: TERMINATED ·Phase: PHASE3

A Study to Examine the Effects of Low and High-fat Meals on Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer Patients

NCT00821054 ·Status: COMPLETED ·Phase: PHASE1

Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive Breast Cancer

NCT03273595 ·Status: UNKNOWN ·Phase: PHASE2

Metabolomics Explores Biomarkers for Metastatic Breast Cancer

NCT04302415 ·Status: UNKNOWN

Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine

NCT04850625 ·Status: COMPLETED

Association of Survival With Maintenance Therapy in Patients With Metastatic Breast Cancer After First-line Chemotherapy

NCT04258163 ·Status: COMPLETED

Study of Etoposide in Treating Patients With Recurrent or Metastatic Breast Cancer

NCT01492556 ·Status: UNKNOWN ·Phase: PHASE2

Low Dose of Metronomic Cyclophosphamide and Capecitabine in Pretreated HER2-negative Metastatic Breast Cancer

NCT01526512 ·Status: UNKNOWN ·Phase: PHASE2

Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer

NCT00320385 ·Status: COMPLETED ·Phase: PHASE3

Real-world Study of Inetetamab in HER2-positive Metastatic Breast Cancer

NCT06305702 ·Status: COMPLETED

Weekly and Every 3 Week Administration of Paclitaxel Liposome Injection in Metastatic Breast Cancer

NCT02142790 ·Status: UNKNOWN ·Phase: PHASE4

Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer

NCT00470704 ·Status: COMPLETED ·Phase: PHASE2

A Real-world Analysis of Concomitant Medication Use Among Metastatic Breast Cancer Patients Treated With CDK4/6 Inhibitors

NCT05141240 ·Status: COMPLETED

Pyrotinib Combined With Capecitabine in HER-2 Positive Advanced Breast Cancer and Brain Metastases (Post-PERMEATE)

NCT05359120 ·Status: UNKNOWN

Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer.

NCT00367471 ·Status: COMPLETED ·Phase: PHASE1

Letrozole Plus Metronomic Capecitabine as First-line Treatment for Patients With Recurrent or Metastatic Breast Cancer

NCT04942899 ·Status: UNKNOWN ·Phase: PHASE2

Pharmacokinetics And Pharmacodynamics Of Lapatinib In Two Dosing Regimens In Treatment-naive Patients With Breast Cancer

NCT00359190 ·Status: COMPLETED ·Phase: PHASE1

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer

NCT00820222 ·Status: COMPLETED ·Phase: PHASE3

Study of Lapatinib in Breast Cancer Patients With HER-2 Non-amplified Primary Tumors and HER-2 Positive or EGFR Positive Circulating Tumor Cells

NCT00820924 ·Status: TERMINATED ·Phase: PHASE2

Lapatinib Ditosylate and Capecitabine in Treating Patients With Stage IV Breast Cancer and Brain Metastases

NCT00967031 ·Status: COMPLETED ·Phase: PHASE2

A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting

NCT01808573 ·Status: COMPLETED ·Phase: PHASE3